CalciMedica (CALC) Enterprise Value (2019 - 2026)
CalciMedica's (CALC) quarterly Enterprise Value came in at -$8.2 million in Q1 2026, up 66.85% YoY from -$4.9 million in Q1 2025, and up 37.28% on a QoQ basis from -$13.0 million in Q4 2025.
CalciMedica (CALC) Enterprise Value (2019 - 2026) Analysis & Trends
CalciMedica (CALC) has 8 years of Enterprise Value data on file, last reported at -$8.2 million in Q1 2026.
- Quarterly Enterprise Value rose 66.85% year-over-year to -$8.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.2 million (up 66.85% YoY) and the FY2025 annual result came in at -$13.0 million, up 30.28% from the prior year.
- Enterprise Value advanced to -$8.2 million in Q1 2026, from -$13.0 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$8.2 million in Q1 2026 to a low of -$48.1 million in Q1 2022.
- A 5-year average of -$23.8 million and a median of -$19.6 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value plunged 66.12% — and 2026, when it soared 66.85%.
- Tracing CALC's Enterprise Value over 5 years: stood at -$33.6 million in 2022, then jumped by 66.51% to -$11.2 million in 2023, then sank by 66.12% to -$18.7 million in 2024, then surged by 30.28% to -$13.0 million in 2025, then surged by 37.28% to -$8.2 million in 2026.
- The last three Enterprise Value figures came in at -$8.2 million (Q1 2026), -$13.0 million (Q4 2025), and -$14.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 2.12 Bn |
| 10 | CalciMedica | 9.92 Mn | -8.70 Mn | - | -18.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.62 Mn |
| Mar 31, 2026 | -8.16 Mn |
| Dec 31, 2025 | -13.02 Mn |
| Sep 30, 2025 | -14.08 Mn |
| Jun 30, 2025 | -30.04 Mn |
| Mar 31, 2025 | -24.63 Mn |
| Dec 31, 2024 | -18.67 Mn |
| Sep 30, 2024 | -20.05 Mn |
| Jun 30, 2024 | -19.14 Mn |
| Mar 31, 2024 | -25.71 Mn |
| Dec 31, 2023 | -11.24 Mn |
| Sep 30, 2023 | -14.59 Mn |
| Jun 30, 2023 | -19.10 Mn |
| Mar 31, 2023 | -43.98 Mn |
| Sep 30, 2022 | -33.55 Mn |
| Jun 30, 2022 | -37.04 Mn |
| Mar 31, 2022 | -48.05 Mn |
| Dec 31, 2021 | -55.07 Mn |
| Sep 30, 2021 | -72.55 Mn |
| Jun 30, 2021 | -73.59 Mn |